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The human genome consists of all the DNA of our species, the hereditary code 
of life. This newly revealed text was three billion letters long, and written in a 
strange and cryptographic four-letter code. Such is the amazing complexity of 
the information carried within each cell of the human body, that a live reading 
of that code at a rate of one letter per second would take thirty-one years, even if 
reading continued day and night.
Francis Collins, The Language of God (Simon & Schuster, 2007, p 1)
The completion of sequencing and mapping of the human genome by Francis 
Collins and others has enabled Dr Parry Guilford from the University of Otago 
Cancer Genetics Laboratory to make a significant difference in fighting gastric cancer 
in an extended Mäori family or whänau with unusually high rates of this disease. 
Dr Guilford spent ten years working with the family. Systematic research led to the 
identification of mutations in the E-cadherin gene amongst family members who 
were highly susceptible to developing gastric cancer. One letter in a code of three 
billion letters was out of sequence. The particular gene is important in cell adhesion 
and structure and is thought to suppress cell invasion; in people with the mutation, 
the gene is switched off. Dr Guilford found that about 70 per cent of people with 
the mutation contract the disease. A relatively simple blood test was developed by 
the researchers and 133 people from the extended family were tested. Forty-seven 
were found to carry the mutation in the E-cadherin gene. Those identified with the 
gene were then screened by a chrome-endoscopy technique which uses coloured 
dyes to enhance the appearance of the cancers. So far, twenty people with very small 
tumours have been picked up through this screening programme. They have all had a 
gastrectomy and are doing well. The other members of the family who were screened 
were found not to have the mutation. Dr Guilford said:
… that’s very significant because right across the family everyone was carrying 
this fear that they were going to get the disease. Now two-thirds of them are 
released from any concern at all, while the others have very good care and cancers 
are being found at a very early stage where their chances of a complete cure are 
extremely high.
The research was funded by the Health Research Council of New Zealand and it shows 
how knowledge of the genetic make-up of a person can be very helpful in preventing 
the onset of disease and removing the fear of disease. Society, and particularly the 
health of the population, has much to gain from the proper use of genetic testing and 
the knowledge that has been derived from the discovery of the human genome.
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Since the completion of the sequencing and mapping of the human genome in 
April 2003, the potential for genetic medicine to be used as a testing, diagnostic 
and treatment tool for multiple diseases is becoming a reality. However, because 
of the predictive nature of genetic diagnosis, there are fears that our future may be 
determined for us by scientists and medical clinicians. There is concern as to how the 
information that is obtained from genetic testing will be used by others. This Report 
analyses the current and future state of genetic medicine, the potential impacts it has 
on society both now and in the future, and the ethical and legal principles that must 
be in place to protect human vulnerability and the integrity of the individual.
This Report covers the use of genetic testing before birth, immediately after birth, 
on children and on whole communities. It explains new genetic tools such as whole 
genome screening for the benefit of clinicians who may be confronted by these 
technologies and the public who may wish to use the new technologies.
The primary purpose of this report is to be as accurate and accessible as possible 
regarding just what can and cannot be done with genetic testing technologies. The 
emphasis is on being as fair as possible in explaining and critiquing the issues that 
emerge from the use of genetic technologies. The researchers who worked on this 
report do not come solely from one discipline. This minimises the possibility of one 
particular mindset – whether it be scientific, ethical, cultural or legal – dominating the 
analyses and recommendations. We have all worked together and argued extensively 
about how to interpret our findings and present them in such a way that the public 
can understand what is at stake in formulating the best possible legal and regulatory 
frameworks for the use of genetic testing in our society.
extenDing the regulatory Framework For 
PreimPlantation genetic Diagnosis (PgD)
In our first Report, we made recommendations on the use of preimplantation genetic 
diagnosis (PGD) in situations where there is potential for a child to be born with a 
serious impairment. In this Report, we look beyond that situation: first, to where 
PGD is used to select what have become known as ‘saviour siblings’. Put simply, 
‘saviour sibling’ refers to the selection of an embryo with cells that can be used once 
the child is born to help treat an already existing child in the family who is ill. At 
present, the guidelines in New Zealand regarding selection of an embryo for this 
purpose are narrow. A major limitation at present is that the child who is ill must 
have a familial genetic disorder. Children who are suffering from an illness which is 
not caused by a familial gene but is the result of spontaneous mutation (for example 
sporadic haemophilia which is not passed down through families but causes serious 
illness for the child) would not have access to this procedure. Such a limitation is 
unjustifiable. The underlying reason for the current limitation is that there will be 

some benefit to the embryo if a familial gene which could cause harm to the embryo 
is not selected. However, this position is unconvincing in the light of arguments as 
to the potential benefits of modification of the current situation. The major benefit 
is that a wider range of sick children, with serious or life-threatening conditions, and 
their families would have access to the option of a saviour sibling, for the benefit of 
the sick sibling and the family as a whole.
We recommend that the current limitation on the use of PGD to select a saviour 
sibling, which requires there to be a familial genetic disease (which means a disease 
that runs through the family), is too narrow. It should be possible to use PGD to 
conceive a child who may provide cord blood for a sick sibling who is suffering 
from, or has suffered from, a condition which is serious or life threatening, but is 
not necessarily a familial disease.
The current guideline restricts creation of a saviour sibling to situations where 
there are no other possibilities for treatment or where tissue is unduly difficult to 
obtain. The problem is that while cord blood from a public registry may contain a 
reasonable match for the sick child, sibling cord blood may constitute the best chance 
for a successful outcome. The current guideline is too onerous and inflexible. The 
emphasis should be on the best possible clinical outcome for the sick child rather 
than, as currently, on exhausting all other clinical options.
We recommend that, while other treatment possibilities and sources of tissue 
should be explored, if the transfer of blood tissue from a saviour sibling confers a 
reasonable chance of a disease-free life for the recipient sibling, that choice should 
be available to the family. 
At present, if a saviour sibling is conceived to help an affected child, the current 
guideline says that the planned treatment for the affected child will utilise only the 
cord blood of the donor child. This limitation exists because of concern for potential 
exploitation of the vulnerable donor child. This guideline is beyond the authority of 
the Human Assisted Reproductive Technology Act (HART Act) 2004 because the Act 
is limited to assisted reproductive procedures and the use of sibling bone marrow for 
transplant which occurs after birth is not within the scope of the Act. The guideline 
is not consistent with current law and practice in relation to naturally conceived 
children whose bone marrow may be used to help a sick sibling.
We recommend removal of the guideline which says the planned treatment for the 
affected will utilise only the cord blood of the future sibling.
There is concern in the research literature in this area that a child brought into the 
world to help treat the illness of another child may be vulnerable to exploitation as 
a potential donor of other tissue and organs. In this argument, the child is denied 
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an open future and is essentially commodified. We note that the law concerning 
donation by children is to be found in well-established common law rules, which 
generally prioritise the interests of that child over the interests of third parties.
We recommend that, if there is to be ongoing donation of blood tissue or bone 
marrow, then it is good medical practice to require the appointment of an 
appropriately qualified advocate for the donor child and an independent physician 
to ensure the donor child is not being exploited. 
We recommend strongly that the Ministry of Health set up a register to record the 
births of all children born to supply blood tissue to a sick sibling so that empirical 
studies may be undertaken on the effects on children who have been donors for 
their siblings.
Some people are carriers of genes that will not harm them in any way but that can be 
passed on to a future generation possibly leading to a serious disorder. The question 
we consider is whether PGD should be used to select against embryos which are 
carriers of a genetic disorder. An embryo that carries, but will not develop, such a 
disorder for the resultant child creates a 25 per cent chance that there will be an 
affected grandchild in the future.
Selection against carrier embryos may be justified on grounds of reproductive liberty 
and the reproductive and psychological interests of the future child. It can also be 
based on the concept of intergenerational benefit, whereby future members of the 
family are no longer at risk of carrying affected embryos. Arguments against allowing 
negative selection of carrier embryos are that it involves the destruction of healthy 
embryos; is an exercise based on genetic essentialism; harms society by reducing 
genetic diversity; and potentially stigmatises healthy carriers. Selection against carrier 
embryos reduces the success of a PGD cycle by reducing the number of available 
embryos, and has resource implications.
On a literal interpretation of the HART Order 2005, where the threshold test is 
‘serious impairment’, negative selection against carrier embryos of X-linked disorders 
is permitted. The purposes and principles of the HART Act 2004 are broad enough to 
permit carrier testing and negative selection both as a contingent procedure to PGD 
and as the primary purpose of testing in the case of X-linked disorders.
The postulated harms of carrier testing are not sufficient to displace the presumption 
of reproductive liberty in this context. The greatest potential for societal harm is that 
prospective parents may feel they have a ‘real choice’ aside from rejecting a carrier 
embryo. This can be dealt with by appropriate information from the clinicians 
involved on a case-by-case basis, rather than outright prohibition; for example, 
prospective parents would have to be informed that the number of available embryos 
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would be reduced and that everyone carries a certain number of recessive mutations. 
Some individuals, for example, are in high-risk ethnic groups with regard to being 
a carrier for certain conditions. Carriers of cystic fibrosis are found with greater 
frequency among people of European descent, while carriers of sickle-cell anaemia 
are found with greater frequency in people of African descent.
We recommend that it should be permissible to choose to select against 
‘carrier embryos’ which carry serious disorders, such as X-linked disorders like 
haemophilia.
The future use of PGD will be influenced by technological advances. A recent 
development involving preimplantation genetic haplotyping (PGH) has the potential 
to increase the number of single-gene disorders that may be tested for and, in the case 
of X-linked disorders, to increase the number of embryos available for transfer by 
identifying unaffected male embryos. PGH was used in the United Kingdom in 2006 
by parents who were both carriers of a cystic fibrosis mutation. The couple already 
had twins, one of whom had cystic fibrosis. With the help of PGH, the couple had a 
second set of twins who were free from cystic fibrosis.
the role oF PuBlic consultation in Decision-making
The Advisory Committee on Assisted Reproductive Technology (ACART) has a 
crucial role in regulating assisted reproductive technology in New Zealand. The HART 
Act 2004, which establishes and provides ACART with direction for its deliberations, 
allows for wide parameters within which the Committee can operate.
The deliberations of ACART and its engagement with the public are an integral 
part of its successful functioning. Given the vital role that the Committee plays in 
regulating assisted reproductive technology in New Zealand, particularly through 
the issuing of guidelines for use by the Ethics Committee on Assisted Reproductive 
Technology (ECART), it is important that ACART takes a considered approach with 
regard to its deliberations.
The HART Act 2004 requires that the Committee undergoes consultation and takes 
public submissions into account in the formation of guidelines. Given the flexibility 
of the HART Act 2004, there are strong democratic reasons in favour of involving 
the public in the development of ACART guidelines. It is therefore important for 
the Committee to establish its approach towards involvement of the public. This will 
assist the Committee in its functioning, and also give members of the public some 
insight into what they can reasonably expect from the consultation process.
The approach that ACART takes regarding the use of information arising from 
public consultation will depend on its overall method of deliberation. The example 
provided by the Environmental Research Management Authority (ERMA) shows a 
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thorough approach towards establishing the deliberative workings of a committee 
adjudicating over ethical matters. The breadth of issues that ACART must consider 
would favour the establishment of a less rigid and less formal approach than that of 
ERMA, while retaining the advantages of robustness.
The information provided through consultation can meaningfully contribute to 
ethical deliberation. It can provide real-world considerations that are likely to 
influence the effectiveness or consequences of ethical policy. It can help to reveal the 
range and nature of interests, and therefore the potential harms, benefits and wrongs 
that should be considered in reaching a decision. The reasoning of the Committee 
should be clear and reasonable.
We recommend that is important for ACART to demonstrate transparency of 
reasoning, especially in relation to the way in which a decision was reached by the 
Committee and why a particular decision was favoured over others that were also 
considered.
newBorn screening: Present anD Future
Currently, in New Zealand, children at birth have their heel pricked to test for 
metabolic conditions which, if found early enough, can be treated. The present New 
Zealand newborn metabolic screening programme is a competent and successfully 
run programme with good detection and participation rates. The programme staff is 
committed to the success of newborn screening, is progressive in attitude towards the 
benefits of screening and fosters good links with other international programmes. 
The programme has avoided negative publicity, and has carefully managed access to 
the Guthrie cards in the interests of maintaining public confidence. New Zealand is 
well placed to have a flexible and responsive screening programme, given the small 
population; the single medical contact for each child (the lead maternity carer); a 
nationally consistent screening panel; centralised testing; and public funding.
New Zealand is following international trends in newborn screening but not in too 
hurried a fashion. Even before expansion, the New Zealand programme was screening 
for a respectable number of serious disorders (more than, for example, the United 
Kingdom). New Zealand has been able to use the implementation lag to absorb 
knowledge about and experience of these new technologies from overseas, and to put 
in place adequate support services, such as the employment of a clinical metabolic 
specialist, before launching tandem mass spectrometry (MSMS) screening.
There is little public awareness of the successful New Zealand newborn programme, 
beyond recognition that the ‘heel prick test’ is a routine procedure for newborns. The 
National Metabolic Screening Programme has been consulting on various aspects of 
the programme and the storage and use of the Guthrie cards. This consultation is a 
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positive move given the anecdotal evidence of growing anxiety surrounding the use 
of DNA samples and Guthrie cards. A small but growing number of parents who 
are requesting the return of the cards points to concern about potential uses of the 
DNA samples. This concern may have implications for the screening programme in 
the future.
We recommend that more public education and information regarding the 
programme, particularly in antenatal classes and on the internet, be made available 
to the general population.
Publications, whether scientific or popular, about newborn screening should be 
made more widely available to parents and members of the public who are seeking 
more information than is currently contained in educational pamphlets.
We recommend that audit, epidemiological and cost-effectiveness data should be 
gathered from the programme.
Given the constrained levels of financial support, and small number of key staff, this 
research would best be done in association with other researchers.
Screening expansion is an exciting move for many and the programme expects that 
an additional five to ten children with genetic disorders will be detected through 
the programme per annum. The MSMS screening is also to be used as a metabolic 
diagnostic tool. Given the expansion of newborn screening, and the versatility of 
the new technology and its potential for disease prevention, the purchase of MSMS 
was perhaps worthy of better governmental support, rather than the programme’s 
reliance on a children’s charity for financial support. 
The newborn metabolic screening programme can be classed as a genetic service. 
At present, there is unofficial and ad hoc national co-ordination with respect to 
genetic services. There is apparently a review underway of the 2003 National Health 
Committee (NHC) report on co-ordination of genetic testing in New Zealand by the 
New Zealand District Health Boards, presumably with a view to implementation of 
at least some of the report; there is no other information available on this review at 
present. Newborn metabolic screening should be acknowledged in future genetic co-
ordination initiatives; though, equally, the programme legitimately belongs within 
the mandate of screening services.
We recommend that when scientifically accurate, clinically useful, cost-effective, 
high-throughput screening processes are available, the pros and cons of inclusion 
of early onset, untreatable disorders, such as lysosomal or peroxisomal storage 
disorders, should be publicly discussed.
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If screening of untreatable disorders is introduced, then there must be improved 
education so that parents are aware of the implications of screening.
In the future, it is likely that DNA screening for individual disorders will be introduced 
as adjunct tests to the metabolic screening programme. In view of the speed at which 
science is developing in genetics, it is impossible to say, with any certainty, what the 
longer-term future holds for newborn screening or even whether the screening time 
point might move to (non-invasive?) antenatal screening. Whole genome sequencing 
remains likely in the future, although how and when this information might be used, 
after the initial sequencing process, remains to be seen.
Expansion of newborn screening into DNA screening will require more 
characterisation of minority populations in New Zealand. It is likely that there will 
be differing allele frequencies for various disorders in these populations, compared 
with populations of Northern European descent (as for cystic fibrosis in the United 
States). It is also possible that a small number of genetic disorders, rarely found in 
Northern European populations, are more commonly found in minority populations 
here. If any were identified, there would be merit in evaluating them for screening. 
We recommend that the current Wilson-Jungner criteria, which have been used 
as a foundation for newborn screening and which were originally formulated in 
1968 for chronic adult disorders, need to be reformulated for newborn screening.
legal issues relating to newBorn screening
Parents should be informed about screening of newborns in terms of their rights 
under the Code of Rights and the uses to which newborn blood samples will be put. 
The analysis in this part of the Report is grounded in the rights-based Code of Rights, 
and takes into account the public health paradigm and how genetic risks are dealt 
with in families. It is important to distinguish public health screening from personal 
clinical services. Traditionally, public health law was prescriptive and compelled 
participation. This is in contrast with the present consumer-based approach which 
actively promotes informed choice and consent, and which seems more in keeping 
with the complexities and sensitivities surrounding genetic medicine.
We recommend that information about newborn screening should be given to 
parents by or during the third trimester, and again before samples are taken from 
the newborn. Parents should be informed about the entire screening pathway and 
what might occur before they take the first step in participating in the newborn 
screening programme. We recommend that clear, unambiguous information be 
given to parents, emphasising that the purpose of participation in the screening 
programme is in the interests of the newborn.
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We recommend that parents or guardians be kept informed throughout the 
screening process, including being notified about the results.
The policy of ‘no news is good news’ may have to be reconsidered in the light of 
complex issues raised by technologies that reveal carrier status and the question of 
whether screening should be extended to include late-onset disorders. 
Activities to monitor and evaluate the programme need to be more explicitly stated 
in information given to parents. Related to this is the importance of distinguishing 
between initiatives taken for the purposes of fulfilling the aims of the programme, 
such as picking up early metabolic conditions and monitoring the programme, and 
those that go beyond the aims of the programme, such as use for general research, 
paternity testing and police investigations.
We recommend that policies regarding retention and use of samples should clearly 
make that distinction and should be explicitly communicated to the public and in 
particular to parents.
The degree and scope of information that can be derived from dried blood spots with 
the use of new and emerging DNA technologies will potentially be very significant and 
have far-reaching implications. There is tremendous long-term value in retention, for 
example, for the purposes of quality management, programme expansion, research 
on testing, and treatment and epidemiological studies. Current and relevant scientific 
literature on the stability of metabolites, DNA extraction and testing technology and 
optimal storage conditions needs to be taken into account with regard to any policy 
development in this area. 
We set out two options for reconciling the inter-relationships between the various 
provisions of the Code of Rights on consent, storage and quality assurance and the 
National Health Committee (NHC) screening guidance. The first option involves 
more actively communicating information about clause 7(9) and clause 7(10) of 
the Code of Rights.
Clause 7(9) provides the right to the return or disposal of blood samples taken in 
the course of a health-care procedure and clause 7(10) involves an exemption to the 
requirement to obtain informed consent for quality assurance (QA) activities such 
as professionally recognised QA programmes, external audits of services or external 
evaluations of services. The second option involves explicitly prescribing, with 
legal authority, a minimum retention period to guarantee all samples are available 
for quality assurance-related activities.
We recommend that policies and procedures setting out, for example, the taking 
and documenting of informed consent be publicly communicated and made more 
widely available to help increase parental and public awareness, understanding 
and confidence.
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new PossiBilities For newBorn genetic screening: 
screening For genetic suscePtiBility to common Disease
Many challenges have been identified since the completion of the Human Genome 
Project, with one of the most significant, perhaps, being how genetic susceptibility 
testing (or genomic profiling) might be integrated into medical practices such as 
newborn screening. 
The review of the psychosocial effects of newborn genetic susceptibility testing has 
highlighted the fact that there are several good reasons to be concerned about such 
testing. These include features inherent in the newborn period; characteristics of 
the tests themselves; and evidence from previous and current newborn screening 
programmes. There remains a relative paucity of empirical research in this area but 
evidence, including the results of research for this Report, is gradually accruing to 
suggest that families generally cope well with type 1 diabetes (T1D) genetic risk 
information concerning their children, if it is conveyed sensitively. At this stage, the 
research remains fairly limited both in focus and duration and the need for further 
research in this area has been highlighted.
Screening children for susceptibility to certain diseases which have a genetic base, for 
example T1D, has the potential to enable parents to ensure that the environment is 
appropriate for a child with the susceptibility. The major concern about widespread 
uses of such screening is that parents may overreact if they find out the child has a 
susceptibility to diabetes and overprotect the child.
In this Report, we have carried out our own research to see what the likely consequences 
would be. We studied three mother-baby cohorts: thirty-eight infants at increased 
genetic risk of T1D, seventy-three at low genetic risk and seventy-six who had not 
undergone testing. Our main focus was to see whether or not the parents who knew 
of the risk would have an urge to overprotect their child and to be overly zealous 
about surveillance. In fact, the outcome was surprising. The group of parents who 
knew their child had an increased risk of T1D were in fact lowest on the anxiety scale 
in terms of how they related to their child. This is only preliminary research but it 
does show that information about a child’s risks does not necessarily lead to parents 
becoming over-anxious. There is potential for such information to empower parents 
to ensure that the environment is healthy for the particular child.
Achieving a proper balance between the social good that may come from performing 
this type of research involving children, and the level of protection offered to child 
participants, is a significant challenge. Such research itself involves complex ethical 
and social issues.
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We recommend that particular attention must be given to minimising risks to 
children and implementing procedures for obtaining the informed consent or 
assent of parents and child participants when screening newborns for genetic 
susceptibility for common diseases. 
Empirical research concerning the potential psychosocial harms of newborn 
susceptibility testing is essential if we are to make rational decisions regarding the 
use of such tests. Analysis of harms and benefits is fundamental to the consideration 
of the introduction of new screening programmes.
Newborn screening for genetic susceptibility is currently only available in research 
settings because of the lack of detailed knowledge concerning harms and benefits; 
the lack of preventative measures; and the relative expense and complexity of testing. 
The research carried out here aims to provide more information on which to base 
decisions about future uses for these tests.
If the pathogenesis of T1D is eventually better understood, and a preventative 
measure developed, even if only partially effective, then the benefits of screening 
may well outweigh the risks. If this eventuates, screening for genetic susceptibility 
to T1D should be reassessed using the usual processes and screening criteria 
applied when considering the introduction of a new test on standard newborn 
screening panels.
genetic testing on chilDren
Genetic testing raises new issues from those involved in other medical contexts, 
particularly for children. Most of the concerns relevant to minors are prompted by the 
familial and predictive aspects of genetic information. Genetic testing may have far 
greater personal implications for other family members than inquiries made in other 
medical contexts, and has the power to be more predictive of future health, which 
has implications for the minor’s best interests and autonomy. Genetic information 
can also be difficult to understand and its implications are easily misunderstood, 
particularly in respect of its predictive power or lack thereof.
As genetic testing increasingly becomes part of regular practice, and is more widely 
available, it seems likely that parents will want to test their children. In our analysis, we 
looked at both children who are too young to give consent to the testing themselves 
and those who have sufficient understanding to give their own consent. With regard 
to very young children, there is a wide range of policy guidelines and some empirical 
research weighing up the risks and harms of testing, which all suggest that it is both 
ethically and legally responsible for parents to test children for conditions for which, 
if detected at an early stage, the environment can be adapted in order to give the child 
the best opportunity of coping with the disease. It is also generally accepted that, if 
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early testing would enable treatment or cure of the disease, then the testing should be 
undertaken – again to give the child the best possible chance of survival. 
The main controversy arises in relation to diseases which have a late onset and 
diseases for which there is no effective cure, such as Huntington disease. In such 
cases, once a person has the genetic markers, the disease will inevitably arise at some 
stage, barring death from unrelated reasons. Child rights advocates argue that these 
decisions, because there is no immediate benefit to the young children, should be left 
to the children once they have sufficient understanding to make their own choices. 
The emphasis is on the children exercising their own autonomy rather than decisions 
being taken for them before they have had a chance to decide whether they wish to 
know about their future health status.
There are two strong objections to this point of view. One of them is that we allow 
parents to make lots of decisions for young children in terms of what they eat and how 
long they stay up at night and, above a minimum threshold, what sort of conditions 
they live in. All of these things have the potential to harm the future autonomy of the 
child and may not necessarily be in the best interests of the child but they are the price 
we pay in order to give parents a sufficient degree of freedom to bring up children as 
they see fit. On this line of reasoning, testing a child at a young age for a condition 
for which there is no treatment is just another parental choice, which may or may 
not harm the child in the future. The choice should be for the parents, because there 
is no overwhelming evidence that the child would be harmed by such early testing. 
The other objection is that within families knowledge about diseases at an early stage 
is inevitable to some degree because of family histories, even without genetic testing 
having been carried out. The testing simply confirms suspicions that are already 
present. If, for example, another member of the family has had Huntington disease, 
there is a reasonably strong chance that a future child in that family group could also 
have that disease. Whether or not the family’s genetic understanding is sufficiently 
sophisticated is another matter; and, of course, the symptoms of Huntington disease 
may not have been identified as such.
A recent poll published by the University of Michigan’s CS Mott Children’s Hospital 
claims that 54 per cent of the 1500 people who responded to the poll (out of a total of 
just over 2000 questioned) thought that genetic testing for disease risk was worthwhile 
even in the absence of treatment, while 30 per cent would want genetic testing for 
themselves or their children only if an effective treatment were available.
A recent 2007 meeting jointly sponsored by the Clinical Genetics Society and the 
British Medical Association concluded that, in the absence of childhood onset or 
the availability of medical interventions, predictive testing for adult-onset disorders 
should not be offered; nor should carrier testing, where the aim of the test is purely 
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to promote the child’s reproductive choice. The results of the meeting showed 
that clinicians generally seemed more sympathetic to respecting a child’s future 
autonomous choice and preferred to delay testing wherever possible. There were 
significant differences between European countries, with Southern and Eastern 
European countries being more likely to carry out carrier testing at the request of a 
parent than Northern or Western European countries.
The United Kingdom, possibly because of the Gillick case which recognised that 
children should be able to give their own consent once they understood the issues 
involved, tends to test minors two years earlier than Germany or France. The meeting 
agreed that imposing a strict age limit for genetic testing is generally inappropriate. 
The meeting concluded that, despite calls in 1994 for prospective and retrospective 
psychosocial research on genetic testing of children, evidence remains sketchy and 
more research is urgently needed. The 1994 guidance identified genetic testing of 
children undergoing adoption as a potential ‘special case’ for testing. It was generally 
felt that special cases for adoption were less justifiable than they had been in the 
1990s.
Professional guidelines on genetic testing of minors take a generally prohibitive stance 
towards genetic testing of minors who cannot give their own informed consent for 
untreatable late-onset disorders. Medical benefits comprise the main justification 
for any genetic testing of children, although special circumstances, in which testing 
may result in greater psychosocial benefits than harms, are considered. There is some 
ambiguity regarding testing for untreatable early-onset conditions. There is less 
consensus regarding carrier testing of minors and fewer recommendations – those 
that exist take a more lenient view of such testing than testing for untreatable late-
onset disorders. 
Many of the professional guidelines, including those applicable to New Zealand 
practitioners (the HGSA Policy on Predictive Testing in Children and Adolescents), 
provide that minors can make their own decisions about genetic testing provided 
that they meet varying standards of competence, understanding and voluntariness. 
There is a variety of evidence regarding the attitudes, awareness and practice of 
different groups of health professionals towards genetic testing of children, despite 
guidance against testing children for untreatable late-onset conditions. Geneticists 
appear more reluctant to test minors, particularly where there are no medical benefits, 
than are other physicians, parents and the general public. Geneticists, other health 
professionals, students, parents and the public give similar reasons regarding the 
appropriateness of genetic testing of minors for non-medical reasons, most of which 
accord with the issues considered in the professional guidelines. Reasons offered in 
favour of testing include parental desire to know; parental autonomy; opportunity 
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for planning; resolution of uncertainty for young people; relieving of anxiety; and 
reproductive decisions. Arguments given against testing include protecting the 
minor’s autonomy; lack of medical benefit; possibility of harm; privacy concerns; 
and concerns over stigma. There appears to be more willingness to provide carrier 
testing of minors than predictive testing. 
There is evidence that health professionals involved in genetics, paediatrics, 
neurology, haemoglobinopathies and other areas of medicine are approached about 
the possibility of genetic testing of minors, and that many health professionals and 
laboratories are acceding to requests, and performing genetic tests on minors. While 
most tests are undertaken for medical reasons, a significant number of tests have also 
been performed for non-medical reasons. 
There is very little evidence available regarding attitudes towards, and the practice 
of, predictive or carrier testing of minors in New Zealand. At this time, requests for 
predictive or carrier testing of minors are very rare, and testing currently proceeds 
on a case-by-case basis.
While there is some professional guidance on genetic testing of minors from the 
HGSA, and laboratory protocols on predictive testing generally, these do not appear 
to be well publicised or formalised. The lack of a formal structure and process for 
genetic testing requests also means that GPs and other health professionals may 
be making inappropriate requests for testing that are not actioned by pathologists, 
resulting in a waste of time and resources, and increased stress for at-risk families 
and children. 
It is vital that GPs and other health professionals know more about genetic testing 
and genetics services in New Zealand, so that they can better facilitate informed 
consent; recognise and acknowledge any limitations in their expertise, particularly 
as they will influence their patients when discussing testing possibilities; know 
when to refer patients for genetic testing; and can offer some degree of genetic 
counselling, if required.
Empirical evidence as to the benefits and harms of genetic testing is very limited. 
However, the most recent and extensive evidence points towards testing having the 
potential to be more beneficial than harmful for competent minors who request it. 
For some of the purported benefits and harms there is no evidence, or only inadequate 
evidence. Other purported harms do not sufficiently justify a decision against genetic 
testing of competent minors upon request because they relate equally to other health-
care contexts; relate to adults also; or can be mitigated or resolved via alternative 
methods, rather than blanket prohibition. Many of the potential harms would not 
be an issue if correct procedures were adhered to, particularly around clear protocols 
and timeframes for counselling and testing and clear rules and procedures regarding 
method, timing and persons to whom disclosure of results will be made. 
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The same limited body of evidence exists against which to judge the effects of genetic 
testing of minors who cannot give their own consent. However, different conclusions 
have been reached because of the different consequences of testing each group. When 
testing a child who cannot give consent is not clinically indicated, there is reason to 
suspect that psychological or social harms may arise from such testing: whether from 
early knowledge that one will inherit an untreatable disorder because one has had no 
say in whether to be tested; because parents may treat the child differently; or because 
of an inability to prevent parental dissemination of one’s genetic information.
We recommend that genetic testing of children who lack capacity to consent to 
genetic testing for non-medical reasons should be treated with caution. Many 
adults choose not to discover their own genetic risk status and the threat to the 
child’s autonomy and right to confidentiality are the reasons for this caution. Also, 
where there is a lack of evidence about what the test results may signify for the 
child’s health, this uncertainty is best dealt with by waiting until the child is able 
to make personal choices.
Predictive genetic testing for an early-onset condition for which no beneficial medical 
interventions exist raises fewer concerns. The same potential benefits exist but not 
the same harms, because the danger to the minor’s future autonomy and potential to 
exercise the right to not know the information is not as salient: the child may never 
reach an age to decide whether to have predictive testing for the disorder (having 
already developed it, or having passed the likely age of onset, unaffected). Thus, the 
putative benefits of such testing (relieving anxiety, preparing for onset, etc.) may be 
weighted more heavily in this context regardless of whether or not the disorder is 
treatable. However, given that there are no clinical benefits to such testing, and that 
there may be some harms (changed parental expectations and treatment of child, 
etc.), parental requests for such testing should still be treated cautiously.
Health professionals generally cannot inform a minor about a heritable condition in 
the family without the permission of the person from whom the health information 
was gleaned (particularly without an explicit request for the information). And yet 
guardians are under no legal duty to inform children of heritable conditions for 
which they may be at risk. Guardians can be advised by a health professional about an 
appropriate age and the manner in which to inform children but families will make 
these decisions for themselves. The available evidence suggests that parents tend to be 
in favour of informing their children of their genetic risks, and of informing them 
themselves, rather than via a health professional. It is, however, obviously a delicate and 
often difficult task, and the ages at which parents consider disclosure appropriate vary.
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As with disclosing familial genetic risk, there currently exists no legal duty to warn 
minors of their genetic test results, and minors might be refused access to their test 
results if the information were considered prejudicial to their interests, or their 
physical or mental health. Deciding whether to disclose a minor’s genetic test result 
requires a careful, case-by-case approach. Parents do not appear to be legally obliged 
to inform their children of their own genetic test results. Genetic counselling will 
be necessary if minors are to be told that they carry a genetic mutation, and may 
be necessary regardless of the test result. The concerns raised by disclosure of the 
information, coupled with those raised by refusing to disclose the information, 
support our argument that carrier or predictive genetic testing that is not clinically 
indicated should generally be restricted to those who competently request it, and 
generally not be permitted on the basis of parental consent alone.
A register should be established to facilitate disclosure to persons who have 
reached the age of sixteen or eighteen years (or earlier if they are competent 
and personally seek access to the information) of the fact that they underwent 
genetic testing as children. Initially, the minors may be informed either that they 
underwent predictive or carrier testing as children, or that some information is 
available about genetic risk status should they wish to access it. 
Such a register is the appropriate method for ensuring that people who undergo 
testing as children are informed of the fact for the following reasons. First, it would 
encourage parents and health professionals to disclose test results to children – as 
the fact of testing will be disclosed to them anyway. Secondly, it gives the person 
tested a choice regarding whether or not to access the information (assuming that 
he or she has not already been told). Thirdly, it avoids the difficulties of imposing 
a new disclosure duty that may have unwieldy and undesirable consequences in 
terms of monitoring, enforcement and sanctions.
Genetic counselling would be required to assist minors in deciding whether to 
access their test results, and to support them whatever their choice. The privacy of 
the register and its information must be strictly maintained.
Parents will usually be aware of their children’s results and can treat that information 
as their own for the purposes of disclosure. Health professionals are bound by 
confidentiality duties to the child and may not disclose the results except to those 
entitled to receive them (usually the guardians) or pursuant to applicable statutory 
or regulatory exceptions.
The child’s privacy interests need to be weighed against the interests served by allowing 
parents to disclose their child’s genetic test results to certain people or agencies, for 
example to school or caregivers (so that they can be alert for early symptoms, etc.), 
and against the parents’ rights to freedom of expression under section 14 of the New 
Zealand Bill of Rights Act 1990. 
17
 Competent minors who have had genetic testing on the basis of their own informed 
consent are entitled to the same rigorous protection of their privacy and confidentiality 
as are adults. This is particularly important in genetic testing because of the greater 
family interest in the information, and the current lack of any legal duty on parents 
or others to keep such information private. 
Community GenetiCs: With PartiCular emPhasis on 
establishinG a mÄori ethiCal FrameWork For GenetiC 
researCh With mÄori
Genetic testing of whole communities is a way of picking up disease trends within 
that community. The diseases will not necessarily be genetically based. They will also 
be influenced by environmental factors. However, long-term studies hold out the 
hope that patterns of living combined with the genetic markers could lead to medical 
break-throughs to improve the health of whole communities. The major question 
here is whether, once a whole community gives up the genetic material for study and 
analysis, they lose control over the information in that material and whether they 
may be harmed by the ways in which the outcomes of the research are interpreted or 
released. We all remember the ‘warrior gene’ news headline in New Zealand when it 
was suggested that a certain gene that was prevalent in Mäori predisposed people to 
act more violently and aggressively. This had potential to deter people from wanting to 
release their genetic material for study. In this Report, we set out an ethical protocol so 
that communities are aware of how their genetic material will be used in research and 
are consulted about the release of the research findings before they are made public.
Indigenous communities have unique concerns in relation to genetic research. The 
impact of genetic information on them as communities is potentially greater than 
the impact on other, less defined, groups. Greater assurance needs to be given that 
the research will be conducted in accordance with robust ethical guidelines and that 
it will meet their expectations. Any research relationship must respect indigenous 
cultural beliefs and be in keeping with their values.
We recommend that researchers explain to the community what the research 
is about and the potential likely findings, and how they would be released, so 
that the particular community can make a choice as to whether or not to be 
involved. Genetic samples should be considered to be ‘on loan’ to the researchers 
for the specific purposes for which consent was obtained. Guidelines for ethics 
committees in New Zealand require researchers to take steps to minimise potential 
harm to participants. The best way to achieve this is to work in partnership with 
participants to ensure that they fully understand what is happening and the 
researcher fully understands the participants and their potential concerns.
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In New Zealand, any research on Mäori health burdens should take steps to minimise 
harm to Mäori arising out of the research. Researchers are required to minimise 
harms, which generally fall into four categories: physical; psychological; social; and 
economic. For research involving Mäori, researchers are additionally obliged under 
the current Operational Standard for Ethics Committees to minimise harms that 
may occur to the whänau (family or community), hinengaro (emotional well-
being and state of mind), wairua (spirit) and tinana (the body or physical self). The 
concept of harm is broad enough to include ‘pain, stress, fatigue, emotional distress, 
embarrassment, cultural dissonance and exploitation’. 
The guidance proposes that minimisation of harm be achieved through inclusion of 
Mäori as ‘partners and participants in the design, implementation, management, and 
analysis of research about Mäori or Mäori health’. Any research on Mäori conducted 
in New Zealand should be based on the principles of partnership, participation and 
protection.
Partnership involves working with iwi, hapü, whänau and Mäori communities to 
ensure Mäori individual and collective rights are respected and protected. Participation 
involves including Mäori in the design, governance, management, implementation 
and analysis of research. Protection involves actively protecting Mäori individual and 
collective rights; Mäori data; and Mäori culture, cultural concepts, values, norms, 
practices and language in the research process.
The guidance describes consultation as the ‘key component’ in developing research 
on a Mäori health issue and is a ‘dynamic and flexible process’ involving a ‘two 
way communication process for presenting and receiving information before final 
decisions are made, in order to influence those decisions’. 
Consultation means:
• setting out a proposal not fully decided upon,
• adequately informing a party about relevant information upon which the 
proposal is based,
• listening to what the others have to say with an open mind (in that there is 
room to be persuaded against the proposal),
• undertaking that task in a genuine and not cosmetic manner, and
• reaching a decision that may or may not alter the original proposal.
The guidance calls for Mäori participation ‘in the governance and management of 
research’, particularly research focusing on Mäori health, and for researchers to ensure 
that Mäori participants have ‘the same protection as all other participants in research, 
19
with particular acknowledgement of cultural diversity for Mäori’. The guidance 
specifically states that this is to include ‘protection of individual and collective rights 
and ownership of data as well as protection from harm’. Researchers are obliged to 
‘support’ and ‘protect’ Mäori culture, language, cultural beliefs, practices, values and 
norms. Importantly in the context of genetic research, ethics committees are asked 
to consider whether mechanisms are in place ‘to ensure the Mäori individuals and 
groups are not marginalised in the research process or by the presentation of the 
research results’.
This Report responds to trends around research on genetic variation and the potential 
for such research to reveal information linking genetic variation to common diseases 
amongst Mäori. The focus is on what has been referred to as the ‘new genetics’, or 
the expanding nature of research on genetic variation that analyses the genetic links 
to common diseases, for example cancer and diabetes, as opposed to single-gene 
disorders and genetic diseases such as Huntington disease. ‘New genetics’ is a phrase 
developed to emphasise the expanding role and rapid development of genetics. 
Shickle defines it as ‘applications resulting from development in techniques for 
locating genes, their products and functions’. The key for this Report about the term 
‘new genetics’ is that it is specifically about studying and identifying the genetics 
of more common diseases (and is not just a study of rare diseases). It involves the 
possibility of much more rapid and large-scale analysis of factors contributing to 
diseases that Mäori and other indigenous peoples suffer disproportionately.
This part of the Report explores the broader context of Mäori health by discussing 
Hauora Mäori frameworks and knowledge systems for addressing health disparities 
and contrasts these with the philosophical and scientific ideals driving ‘new genetics’. 
As links between genetic variation and the health of certain populations, particularly 
indigenous and ethnic populations, continue to be made the issues that arise are 
primarily driven by ethical, cultural, social and political influences. This research 
involved analysing the relationships between potential health benefits from genetic 
testing of newborns and any cultural, spiritual or ethical issues this testing may 
raise. It looked at the tensions between Mäori collective tribal responsibilities and 
individual rights with regard to the access to and use of human genetic material. 
This Report proposes that genetic testing research could have significant benefits 
for Mäori and other communities particularly if a broad approach to establishing 
and implementing moral, ethical and spiritual frameworks to drive such research is 
adopted.
This part of the Report introduces the Mana Protocols for genetic research and 
outlines how such protocols could be developed and used to assist Mäori (whänau, 
hapü and iwi), researchers, funders and regulators of genetic research.
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We recommend that a Mäori ethical framework for genetics, to be administered by 
a Mäori ethics committee or similar body, should be established. While legitimate 
concerns have been raised about the genetic testing of ethnic and indigenous 
communities, equally strong sentiments have been expressed warning that we 
should be careful ‘not to throw the baby out with the bath water’. The key is to 
ensure that the approach to genetic research is balanced in terms of its risks and 
benefits, and that we do not give genetics a more negative or positive spin than 
is justified. The need for honesty is paramount. There are many talented and 
committed Mäori and non-Mäori genetic researchers who believe their science can 
make a significant contribution to the improvement of community well-being. If 
genetic research is to be conducted with kaupapa wairua Mäori as its foundation, 
the benefits will be significantly enhanced.
new genetic testing technologies
The use of microarrays allows many genetic tests to be done simultaneously on one 
genetic sample and changes (mutations) to be found that are currently not detected. 
Microarrays are being used predominantly in the research sector. There has been 
some movement into the clinical testing and diagnostics arena internationally, but 
its eventual utility in clinical screening remains to be seen. The diagnostic aspect of 
microarrays has been enthusiastically reported in the clinical and scientific literature 
and remains one of the most likely uses of the technology as the cost comes down.
There is still a technology block regarding the use of microarrays with PGD for 
aneuploidy screening in the form of whole genome amplification. If this problem can 
be overcome, microarrays could conceivably make a positive difference to implantation 
rates and reduce miscarriage rates for those who choose to use PGD for this purpose. 
PGD requires, however, that in vitro fertilisation (IVF) be used to generate embryos 
for testing. It is therefore unlikely that it will ever be used outside fertility clinics and, 
even then, only for a subset of clients. Future use remains debatable. 
As the cost comes down, microarrray technologies will likely supersede the existing 
cytogenetic technologies as a first-line prenatal test. Arrays are faster and potentially 
offer more detailed screening for disorder-causing chromosomal changes. This 
does not preclude simultaneous karyotyping as a method of confirming any 
larger abnormalities, or the use of other techniques for later confirmation of an 
abnormal result. All cytogenetic results should be confirmed, preferably by using 
another method. As knowledge increases regarding the effects of medium to large 
chromosomal changes, (ironically) through increased testing as well as new research 
data, uncertainty about the seriousness of particular changes will be reduced.
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There remains, however, the difficulty of explaining the technology and results to a 
lay audience. A number of other ethical issues have been raised around the use of 
microarrays for prenatal screening. In addition, microarray use in prenatal screening 
currently requires an invasive procedure to obtain fetal material for testing. Again, 
unless there are developments in non-invasive testing, this technology will be limited 
to those women already undergoing amniocentesis or chorionic villus sampling.
A debate is underway regarding how much genetic information is useful and the 
advantages and disadvantages of selective versus whole genome screening. There is a 
corollary with the use of whole-body CAT and MRI scans for simple health ‘check-ups’. 
Abnormalities may be detected that have no effect on the quality of life but, because 
they have been found, they are investigated or treated unnecessarily. The more targeted 
the microarrays to specific clinical questions, the less likely this is to occur.
Genetic services in New Zealand are currently stretched. Introduction of the routine 
use of microarrays would require a substantial investment, not only in technology 
and laboratory staffing, but also in clinical genetics and counselling personnel.
Implementation of new testing technologies in New Zealand currently appears to 
be driven by the clinical testing laboratories, on a cost recovery basis. There appears 
to be no national strategy for monitoring and introducing new techniques and 
technologies. While this is not necessarily a negative, it may preclude a national push 
for the introduction of new genetic testing tools; particularly if this were to be based 
in a single laboratory in competition with others. In addition, private genetic testing 
services have not been established in New Zealand or Australia. This may or may 
not affect whether laboratories offer new services. The promised follow-up to the 
2003 report by DHBNZ on molecular genetic testing in New Zealand is said to be 
underway. We await the report with some anticipation.
Beyond microarray technologies, rapid whole genome sequencing is being touted 
as the next revolution in genetic testing. It is likely that rapid whole genome 
sequencing will become viable in the medium to long term. This technology reveals 
the ultimate genetic information – the exact sequence of the genomic DNA. This 
information is superior to the limited data from microarrays, although it is likely 
to need more interpretation. It is unlikely, however, to detect ploidy changes, such 
as trisomies, without additional analysis. Detection of chromosomal copy number 
variation (CNV) is the principal driver of most current and future PGD, prenatal 
and diagnostic testing. 
Array comparative genomic hybridisation (aCGH) represents a major advance in 
the field of cytogenetics and offers tremendous promise in prenatal diagnosis for the 
detection of genetic alterations leading to serious genetic conditions. This technology, 
also sometimes known as molecular karyotyping, can detect differences in DNA 
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copy number at hundreds or thousands of points in the genome simultaneously. 
This technology promises to replace standard karyotyping, which uses standard 
microscopy to view chromosomes directly in order to detect structural variations that 
lead to conditions such as Down syndrome (which can be caused by trisomy 21, that 
is three copies of chromosome 21 instead of two, or a joining of chromosomes 21 and 
14) or Turner syndrome (loss of one copy or part of one copy of the X chromosome 
in girls), or genetic duplications, deletions, insertions or translocations (some of 
which can be associated with hereditary diseases or cancers). Compared to standard 
karyotyping, aCGH can detect genetic variations at a much higher resolution. 
Array comparative genomic hybridisation was initially studied and utilised in cancer 
genetics to determine how chromosome structure and function contributed to tumour 
development. Although it is still used for this purpose, it is hoped that aCGH will be 
valuable in other clinical contexts, including prenatal screening and diagnosis. In 
research, aCGH has demonstrated an unparalleled ability to perform comprehensive, 
high-resolution scans of both the whole genome and specific chromosomal regions. 
Physicians are looking to aCGH to increase their ability to detect clinically significant 
genetic alterations. Although it is already a powerful research tool, the technology 
is still in its early stages and has not fully transitioned to clinical use. However, in 
the United States, aCGH is already being offered as a clinical test in postnatal and 
prenatal settings. More research is necessary to determine how and in what capacity 
aCGH technology can and should be used for clinical prenatal screening or diagnosis. 
A necessary aspect of this development is a thorough consideration of the ethical 
implications of the new technology; this will come to the forefront as clinical use of 
aCGH increases.
At this stage of the development of aCGH technology, a number of recommendations 
can be made for clinical use. These recommendations should be revisited as 
information about its clinical validity and utility is obtained, and as the accuracy, 
resolution and cost of aCGH-based tests evolve.
First, aCGH should be used for prenatal testing only under research protocols 
where other data necessary for learning how to interpret aCGH data are also 
collected.
This information might include the results of other prenatal screening tests (such as 
nuchal translucency and multiple-marker blood tests) and clinical data on parents. 
The aCGH data should be validated by and compared to data from some other 
method such as standard karyotyping, FISH and QF-PCR.
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Secondly, before clinical use as a prenatal test, aCGH should be used and evaluated 
under conditions that allow assessment of the clinical significance of the results 
(i.e., where phenotype and clinical information about the patient are available 
from newborns, children or adults).
Given the large amount of copy-number variation in the general population, even 
among apparently healthy people, the finding of copy-number variants may in 
itself be of unclear clinical significance. In the prenatal setting, very little clinical 
information can be obtained to aid in the interpretation of aCGH results, and it is 
thus not the optimal setting in which first to bring the technology to clinical use.
Thirdly, laboratories beginning to use aCGH should adopt uniform and 
transparent technical standards, including standards regarding what constitutes 
the ‘normal’ control samples with which patient samples are compared.
Fourthly, research and clinical laboratories using aCGH should anticipate the 
possibility of uncovering ‘incidental’ findings and make plans for handling them.
For example, if parental samples are tested, in order to interpret the findings from a 
fetal sample tested to detect trisomy 21, the laboratory should make advance plans 
for whether and how to report unexpected findings of major clinical significance that 
arise in the parental samples. Laboratories should also decide whether any results will 
be withheld.
Fifthly, informed consent to aCGH in research or clinical settings should include 
provision for how research subjects or patients want to handle ‘incidental’ findings, 
the possibility of unwanted results and results of unknown clinical significance.
The diagnostic power of aCGH technology offers an exciting and revolutionary 
approach to prenatal diagnosis, providing a much more fine-tuned tool for genetic 
analysis than other currently available technologies. The detection capability, as a 
result of increased resolution, the comprehensive nature of the tests and the potential 
for faster reporting times, makes aCGH a promising new technique. However, 
despite the documented successes of this technology so far, more research is needed 
to understand its scope fully so that aCGH can be implemented as a clinical tool in 
prenatal diagnosis. Because the technique has not yet transitioned to clinical use, there 
are as yet no established standards for its application. To be sure, ethical difficulties 
and ambiguities will attend its clinical use. Research will no doubt continue to 
improve the technology; but it is also important that the ethical, legal and social 
implications are given serious consideration as aCGH transitions to clinical use.
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conclusion
The main finding which comes through in all aspects of this Report is the current 
lack of awareness and understanding of the benefits that genetic testing can bring to 
the health of individuals, families and communities. This lack of understanding and 
awareness is not simply within the general population but also among the medical 
profession, because many doctors were trained before the discovery of the human 
genome. Discovery of the human genome raises a whole new and different way of 
looking at the current and future health of individuals and communities. While 
genetic testing technologies are still emerging, their potential to provide information 
which will help people understand their health status in a better light is clear. The 
information that is obtained as a result of genetic testing has the potential to be 
misused or misunderstood. However, that is true of any information and should not 
be cited as a reason to deter us as a society from obtaining the information and 
subjecting it to careful analysis.
The full impact of the discovery of the human genome has not yet fulfilled the potential 
promise to help us understand the genetic structure of all diseases because the nature 
of disease and the interaction of genetics with the environment is complex. For the 
advancement of society, we must continue to explore the full potential of the meaning 
of our genetic make-up with an open mind. Throughout this Report, we provide legal 
and ethical frameworks to ensure that the potential for misuse of genetic information 
is avoided as much as possible. Overall, the benefits of genetic testing for the health 
of individuals and populations outweigh the potential harms and we hope that the 
frameworks in this Report will minimise the impact of those harms. 
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